Guide

How to Evaluate a Peptide Vendor: A Complete 20-Criterion Framework

Last updated: April 18, 2026 · 16 min read · Reviewed by Grey Peptides Editorial Board

TL;DR

Peptide vendors vary enormously in quality. The difference between a vendor who publishes per-batch HPLC chromatograms with third-party lab verification and one who claims "99% purity" on a marketing page is the difference between a verifiable product and an unverifiable one — and the price difference between them is often small. This guide walks through the 20 criteria that matter, organized into five categories by their actual importance for safety and quality:

  • Quality & Purity (40%) — COA availability, HPLC purity, mass spec, third-party testing, endotoxin/sterility
  • Manufacturing & Sourcing (20%) — manufacturer transparency, product form, vial quality, lyophilization
  • Shipping & Logistics (15%) — speed, packaging, discretion
  • Business Practices (15%) — pricing, customer service, refunds, longevity
  • Communication & Information (10%) — education quality, legal labeling, review transparency, community standing

The companion Vendor Evaluation Framework tool lets you score any vendor against all 20 criteria and compare up to four vendors side-by-side. This article explains what to look for at each criterion — what good, adequate, and bad look like — so your scoring is calibrated.

→ Use the Vendor Evaluation Framework to score vendors as you read.

Why this framework exists

Grey Peptides does not recommend, link to, endorse, or rate specific vendors. We will not tell you "buy from X." What we will do is teach you to evaluate any vendor yourself, using the same criteria that experienced buyers use.

This is deliberate. The peptide market is a moving target — reputable vendors of 2024 are not always reputable in 2026, and good vendors occasionally change hands, change manufacturers, or change standards. A framework that teaches evaluation is more durable than a list that gets stale.

It also sidesteps the real legal and ethical tension of vendor recommendations. Most peptide vendors operate in a gray zone — research-chemical labeling, offshore manufacturing, a customer base that treats "not for human consumption" as a shipping formality. Naming vendors inevitably steers readers toward specific operations, with all the legal, regulatory, and quality-drift risks that entails. A framework does not.

So this is what we'll do: walk through each criterion, explain what it tells you, and give you specific things to look for.

Category 1: Quality & Purity (40% of score)

This is the category that actually matters for safety. Injecting something means injecting every impurity in the product — residual solvents, process-related peptide fragments, truncated sequences, microbial contamination, endotoxins from bacterial breakdown. These are not hypothetical concerns. They are the reason pharmaceutical products cost what they cost.

Five criteria in this category. Weighted most heavily because nothing else matters if the product isn't what the label says or contains things it shouldn't.

1.1 Certificate of Analysis (COA) availability (weight: 5)

A Certificate of Analysis is a lab report documenting a specific batch's properties — identity, purity, appearance, moisture content, and often sterility and endotoxin results. It's signed and dated, references a specific lot number, and should match the lot number printed on the vial you receive.

What good looks like: Every product page links to the current COA, with the lot number visible. When the batch changes, the COA changes. You can cross-reference the lot number on the vial against the PDF.

What adequate looks like: COAs available by email request, promptly delivered.

What bad looks like: No COAs, "available on request" but unresponsive requests, or a single static COA that never changes across batches.

This is a baseline criterion. A vendor that cannot or will not produce a current COA for their current batch is telling you they either don't have the testing done or don't want you to see it. Both are disqualifying.

1.2 HPLC purity reporting (weight: 5)

High-Performance Liquid Chromatography separates the components of a peptide sample and measures the purity of the target peptide relative to related impurities. HPLC purity is the industry-standard purity metric for peptides.

Research-grade peptides typically report ≥98% purity. Pharmaceutical-grade is ≥99%. The difference is meaningful: a 98% pure sample contains 2% related impurities (typically truncated or incorrectly folded peptide variants); a 99.5% sample contains five times less. Those impurities are still peptides, and they can have their own biological activity.

What good looks like: Actual chromatogram image posted (not just a stated percentage), with ≥99% purity clearly labeled on the trace, batch-specific.

What adequate looks like: Chromatogram posted with ≥98% purity, or high-purity claim with chromatogram available on request.

What bad looks like: Percentage claimed with no chromatogram. "Greater than 99% purity" text with no underlying data is marketing copy, not verification. You cannot confirm a claim you cannot see.

A chromatogram that shows a clean single peak at the expected retention time, with no significant secondary peaks, is what you want to see.

1.3 Mass spectrometry confirmation (weight: 3)

Mass spectrometry measures molecular weight. For a peptide, this confirms identity — that the product has the expected molecular mass for the stated sequence. This is separate from purity. A sample can be 99% pure and be the wrong peptide. Mass spec catches that.

Any vendor doing serious quality control does mass spec. Whether they share the spectra is the question.

What good looks like: Mass spec confirmation posted alongside the COA. You can see the m/z value (mass-to-charge ratio) matching the theoretical molecular weight of the peptide.

What adequate looks like: Mass spec performed and available on request.

What bad looks like: Identity not verified, or "verified" without data.

Note: For small peptides (under 4 kDa), LC-MS is standard. For larger peptides like tirzepatide or semaglutide, MALDI-TOF or ESI-MS is typical. Either is fine; the point is that identity was confirmed independently of the synthesis.

1.4 Third-party lab testing (weight: 4)

There's a meaningful difference between a vendor's in-house lab testing their own product and an independent accredited lab doing it. In-house testing can be legitimate, but the incentive structure is problematic: the same organization that makes the product is grading it.

What good looks like: Every batch tested by a named independent lab. The lab is accredited (ISO 17025 is the relevant standard for analytical labs), and its name appears on the COA.

What adequate looks like: Third-party testing on some batches or on request.

What bad looks like: In-house testing only, or no testing disclosed.

The named third-party lab is the detail that matters. "Independently tested" without naming the lab is not independently tested; you cannot verify a lab that isn't named.

1.5 Endotoxin and sterility testing (weight: 3)

Endotoxins are lipopolysaccharides from gram-negative bacterial cell walls. They are stable to heat and remain biologically active even after bacteria are killed, and they are the most dangerous contaminant in injectable products. At low doses they cause fever and inflammation; at higher doses, septic shock. Standard testing uses the LAL (Limulus amebocyte lysate) assay.

Sterility testing confirms the finished product is free of viable microorganisms. For lyophilized peptides, sterility is tested before or after the lyophilization step depending on process design.

What good looks like: Both LAL endotoxin and sterility results published per batch, meeting USP limits.

What adequate looks like: Sterility tested, endotoxin level not disclosed.

What bad looks like: Neither tested or disclosed.

For anyone taking peptide quality seriously, endotoxin testing is not optional. The reason injection site redness and flu-like symptoms sometimes occur with research-grade peptides is, often, endotoxin contamination. Pharmaceutical products are held to strict endotoxin limits for exactly this reason.

Category 2: Manufacturing & Sourcing (20% of score)

Four criteria covering where the product comes from and what form you can buy it in. These affect both quality and price transparency.

2.1 Manufacturer transparency (weight: 3)

Most peptide vendors are not manufacturers. They are resellers of product made by a relatively small number of contract peptide manufacturing facilities, many of them in China. There is nothing inherently wrong with this — contract manufacturing is how the majority of pharmaceutical APIs are produced worldwide — but opacity about the supply chain is a red flag.

What good looks like: The vendor discloses either that they manufacture in-house (rare and premium-priced) or names a specific contract manufacturing partner. If the partner is named, you can research the partner's reputation separately.

What adequate looks like: Country of origin disclosed but not specific facility.

What bad looks like: No manufacturing information at all.

A vendor that describes itself as "American-owned" but won't say where the product is made is, in most cases, importing from Asia and repackaging. That is not necessarily a quality problem — but hiding it is a transparency problem.

2.2 Product form: kits vs single vials (weight: 2)

Peptides are typically manufactured and shipped from bulk facilities in standardized packaging called "kits," which are usually boxes of 10 vials of identical product. Vendors who sell single vials are, most of the time, buying kits and splitting them — selling individual vials at a markup that reflects the service they're providing (smaller purchase quantities, domestic shipping, customer support, replacement guarantees).

This is a legitimate service model. Someone who wants one vial of BPC-157 to try for a month shouldn't have to buy ten. But the economics matter. A kit of BPC-157 that costs a domestic reseller $200 should not produce ten single vials selling for $200 each. That's not a 10% markup for service; that's a 10× markup.

What good looks like: Transparent kit, bulk, and single-vial pricing so customers can buy at the scale that matches their protocol without overpaying for smaller sizes.

What adequate looks like: Single vials with reasonable relative pricing (2–3× cost, not 10×).

What bad looks like: Single vials only at kit-split prices, with no option to buy in bulk.

You can sometimes estimate a vendor's sourcing cost by looking at per-vial prices in their 10-vial packs versus their single vials. A reasonable ratio is 50–70%; a suspicious ratio is 20–30%, which suggests the single-vial price is heavily inflated relative to cost.

2.3 Vial and stopper quality (weight: 2)

Pharmaceutical injectables use Type I borosilicate glass vials (chemically inert, doesn't leach) and bromobutyl rubber stoppers (low gas permeability, good resealing after needle puncture). Lesser-quality vials can leach silicone or alkali metals into the product; lesser stoppers can fail to reseal or shed rubber fragments when repeatedly punctured.

What good looks like: Type I glass vials, bromobutyl stoppers, properly crimped with intact seals. Labels adhere well and are legible.

What adequate looks like: Standard research-grade vials without visible quality defects.

What bad looks like: Loose caps, flaking lyophilate that suggests moisture contamination, poorly adhered labels, cracked vials, visible rubber particles in reconstituted product.

This is partly assessed by reading reviews and partly by what you see when your own order arrives. The first vial is a data point for all the rest.

2.4 Lyophilization quality (weight: 2)

Lyophilization (freeze-drying) removes water from the product while keeping it stable and shelf-stable. A properly lyophilized peptide appears as a white puck (a cohesive disk at the bottom of the vial) or a fluffy, uniform white powder. A poorly lyophilized product may appear collapsed, melted (glass-like), fragmented, or yellow-tinged.

Appearance issues indicate either process problems during lyophilization or temperature excursions during transport. Neither is necessarily fatal to the product — reconstitution and HPLC testing of an affected vial would tell you whether the peptide itself is intact — but it is a quality signal.

What good looks like: Consistently clean, intact lyophilate across customer reports.

What adequate looks like: Occasional minor issues, typically replaced by the vendor.

What bad looks like: Frequent reports of collapsed, melted, or visibly degraded product.

Category 3: Shipping & Logistics (15% of score)

Three criteria. Peptides are temperature-sensitive, so shipping directly affects what you actually receive.

3.1 Shipping speed and tracking (weight: 2)

Lyophilized peptides are more heat-stable than reconstituted ones, but extended transit at warm temperatures still accelerates degradation. Fast, tracked shipping limits exposure and gives you recourse if the package is lost.

What good looks like: Fast options (overnight or 2-day) available, all shipments tracked, cold packs included for temperature-sensitive peptides in warm months.

What adequate looks like: Standard 3–7 day shipping with tracking.

What bad looks like: Slow, untracked, or unreliable shipping. Packages routinely lost.

3.2 Packaging quality (weight: 2)

Glass vials break. The packaging needs to protect them through handling by multiple carriers. Insulation matters for temperature, and padding matters for physical integrity.

What good looks like: Insulated box, ice packs when warranted, tamper-evident seals, vials well-padded and unlikely to move during transit.

What adequate looks like: Adequate bubble wrap or foam padding, rare breakage.

What bad looks like: Minimal padding, frequent reports of broken vials on arrival.

3.3 Packaging discretion (weight: 1)

Many buyers prefer that the exterior of the package not advertise the vendor, both for personal privacy and because distinctive packaging can attract attention during transit.

What good looks like: Fully discreet packaging by default — plain box, generic return address, no visible branding.

What adequate looks like: Generic exterior without obvious branding.

What bad looks like: Company logo prominently displayed on exterior.

Lower weight than the other two in this category because it's about preference rather than product quality. But for many buyers, it matters.

Category 4: Business Practices (15% of score)

Four criteria covering how the vendor runs as a business. These predict how they'll handle problems — because problems happen, and how they're handled tells you everything.

4.1 Pricing transparency (weight: 2)

You should be able to see total cost — product, shipping, any fees — before you commit. Hidden costs added at checkout is a trust problem.

What good looks like: Prices clearly posted, shipping cost calculated in the cart, free shipping thresholds disclosed, no surprises at checkout.

What adequate looks like: Clear prices with shipping calculated at cart.

What bad looks like: Prices hidden behind "contact for quote" requirements, or checkout adds significant fees not previously disclosed.

4.2 Customer service responsiveness (weight: 2)

How quickly they reply to emails and how useful their answers are. This predicts how they'll handle actual problems.

What good looks like: Same-day responses, replies from someone who actually understands the product and can answer substantive questions.

What adequate looks like: Response within 48 hours, helpful answers.

What bad looks like: Days to respond, canned non-answers, unresponsive to specific questions.

Test this before you order. Send a technical question ("What's the endotoxin level on your current batch of TB-500?") and see how they respond. The answer and the speed of reply tell you a lot.

4.3 Refund and replacement policy (weight: 2)

Vials break in transit. Packages get lost. Lyophilate occasionally looks wrong. A written policy is protective; its absence is a warning.

What good looks like: Explicit policy covering shipping damage, loss, and visible quality issues, with clear documentation requirements (photos of damage, etc.).

What adequate looks like: Replacement policy for shipping damage or loss.

What bad looks like: No stated policy, or "all sales final" language. You bear all risk.

4.4 Business longevity and reputation (weight: 2)

New vendors aren't automatically bad — everyone starts somewhere. But a track record provides evidence a list of claims does not.

What good looks like: 5+ years of operation under the same name, consistent reputation across that period.

What adequate looks like: 2–5 years active, stable reputation.

What bad looks like: Under 1 year, or rebranded from a previous name (often a warning sign that the previous name accumulated complaints).

Check the domain registration date with a WHOIS lookup. Check the archive.org Wayback Machine for when the site first appeared. These provide ground truth that marketing pages don't.

Category 5: Communication & Information (10% of score)

Four criteria covering how the vendor presents itself and its products. Lowest weight category because this matters less than quality and manufacturing, but it's still a real signal.

5.1 Educational content quality (weight: 1)

Does the vendor provide real scientific information or marketing copy? A vendor who cites actual research papers and explains mechanisms accurately is different from one who promises miracles.

What good looks like: Deep research summaries, peer-reviewed citations, accurate mechanism explanations.

What adequate looks like: Useful information with some citations.

What bad looks like: Pure hype, unsubstantiated claims, "this peptide cures X" language.

In the United States, peptides sold as research chemicals are legal only when sold for research purposes with appropriate disclaimers and not marketed for human consumption. Vendors who wink at this line — technically labeling products as research-only while marketing them clearly for human use — are inviting regulatory trouble for themselves, and potentially for customers.

What good looks like: Consistent research-only framing throughout. Product descriptions don't describe dosing for human conditions. Disclaimers present and meaningful.

What adequate looks like: Disclaimers present but marketing copy is borderline.

What bad looks like: Products explicitly marketed for human conditions ("lose weight with our semaglutide"). This is the clearest regulatory red flag and suggests the vendor either doesn't understand or doesn't care about the legal framework they operate in.

5.3 Review transparency (weight: 1)

Real vendors have real reviews. Real reviews include some negative ones, because no vendor is perfect. A review section with 100% five-star reviews and no complaints is suspicious.

What good looks like: Verified-purchase reviews including some negative, with vendor responses that substantively address complaints.

What adequate looks like: Real reviews including some negative.

What bad looks like: No reviews at all, or suspiciously uniform five-star reviews with no critical feedback visible.

5.4 Independent community standing (weight: 2)

What do informed communities say about this vendor? This is higher-weight than other communication criteria because independent community assessment is less susceptible to manipulation than on-site reviews.

What good looks like: Consistently positive assessment across multiple independent communities — Reddit (particularly specific peptide subreddits), established forums, and protocol-focused discussion groups.

What adequate looks like: Generally positive with minor recurring complaints that are reasonable.

What bad looks like: Recurring negative reports about quality, shipping, or customer service across independent sources.

A note on forum culture: some peptide communities have strict rules against naming vendors explicitly — users discuss them by initials, abbreviations, or coded language. This is a feature of those communities, not a limitation; it means you often need to spend some time reading before the signal becomes clear. Reddit's r/Peptides and related subreddits prohibit direct vendor naming but allow discussion of vendor properties, which is actually more useful for evaluation than a list of names.

How to use the framework

Score as much as you can, but don't force answers. The framework tolerates missing data — unscored criteria are excluded from the calculation, and the completion percentage tells you how confident the overall score is. A vendor evaluated on 15 of 20 criteria may have a more meaningful score than one where you guessed at the remaining 5.

Interpret categorically, not just totally. A vendor that scores 80 overall but 50 in Quality & Purity is not actually a good vendor — they're a well-run business selling unverified product. The category weights reflect our editorial view of what matters; specifically:

  • Quality & Purity at 40% is intentional. For injectable products, purity and sterility are non-negotiable.
  • Manufacturing at 20% reflects that the upstream supply chain drives quality at least as much as the vendor's own practices.
  • Shipping, Business, and Communication each matter, but none individually should compensate for weak Quality & Purity scores.

Compare vendors honestly. The tool supports up to four vendors side-by-side because that's usually the most anyone needs to compare. If you find yourself with more candidates, narrow first using deal-breakers (no COAs? gone. No endotoxin testing? gone.) before investing full evaluation time.

Re-score periodically. Vendors change. Manufacturers change. Standards drift. A vendor that scored 85 a year ago may score 70 now, or vice versa. The framework is reusable; save your evaluations, re-score at intervals, and watch for trends.

What the framework cannot do

Three honest limitations worth stating.

It can't tell you about current batches. Even a vendor with a strong historical reputation can ship a bad batch. Nothing substitutes for reading the COA for the specific batch you're receiving and, if it matters enough, sending a sample for independent testing.

It can't rank by price. Price is deliberately not weighted. Lower price is not inherently worse, and higher price is not inherently better. What matters is whether the price is justified by what you're getting — that's a judgment you make, not one we encode.

It can't replace community intelligence. The community standing criterion partially addresses this, but staying current on peptide forums and discussion groups is part of being an informed buyer. Vendors that were excellent in 2023 may not be in 2026; the framework helps you evaluate any vendor, but it does not automate the ongoing effort of paying attention.

Frequently asked questions

Should I choose the highest-scoring vendor? Usually, but not always. Consider your specific use case. A vendor with perfect Quality & Purity but slow shipping may be wrong for you if you need product immediately. A vendor with adequate quality and excellent business practices may be fine for a low-stakes purchase. The score is a diagnostic tool, not a verdict.

What if I can't answer most of the criteria? That tells you something important — the vendor is opaque. Opacity is itself a data point, and a vendor about whom you can answer fewer than half the criteria is a vendor you know very little about. Your completion percentage is part of the evaluation.

Do international vendors score differently? Not structurally. The criteria apply regardless of jurisdiction. However, some criteria (refund policies, customer service speed) often trend lower for international-direct vendors because of language, time zone, and logistics differences. This is context for your interpretation, not a change to the framework.

Does a low price correlate with low quality? Sometimes, but not reliably. Kit-splitting markup is the dominant pricing factor in the research-chemical market, not quality differences — the same batch of peptide may be sold by ten different vendors at wildly different prices. Price is a weak signal at best. Quality & Purity criteria are strong signals.

Should I trust affiliate-based review sites? Most peptide "top vendor" review sites are affiliate operations earning commission on referrals. This doesn't automatically make their information wrong, but it makes their ranking suspect. If a site strongly recommends a specific vendor and offers a coupon code, assume affiliate relationship and weight their assessment accordingly.

Sources and further reading

For the bigger picture behind any of these criteria — how the US peptide market actually works, the difference between the pharmaceutical, research-chemical, and overseas channels, what FDA enforcement looks like in practice, and what testing actually detects — see our Peptide Sourcing Knowledge Base. It is the companion to this framework: the framework scores individual vendors; the Knowledge Base explains the market they operate in.

→ Now try the Vendor Evaluation Framework — score up to four vendors and compare side-by-side.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.

← All articles